Related Experiment Video
Updated: Oct 17, 2026
Fertility Sparing Procedure using Carbon Dioxide Fiber Laser Vaporization of Ovarian Endometrioma
Published on: July 6, 2022
No significant leukocytosis under controlled ovarian stimulation using the LHRH antagonist Cetrorelix and recFSH
M Ludwig1, D Strik, R Felberbaum
1Department of Gynecology and Obstetrics, Medical University of Lübeck, Ratzeburger Allee 160, 23538, Lübeck, Germany. ludwig_m@t-online.de
Objective:
To study the influence of an LHRH (luteinizing hormone releasing hormone) antagonist protocol (Cetrorelix) and the use of recombinant follicle-stimulating hormone (FSH) on the development of leukocytosis, compared to the use of urinary HMG (human menopausal gonadotrophin).
Design:
Prospective, randomized phase III clinical trial.
Setting:
Infertility day clinic, Department of Gynecology and Obstetrics.
Patients:
Thirty patients undergoing IVF/intracytoplasmic sperm injection (ICSI) treatment following controlled ovarian stimulation using a multiple dose protocol and the LHRH antagonist Cetrorelix.
Main Outcome Measure:
Differences in white blood cell (WBC) count before stimulation, during the follicular phase and in the midluteal phase.
Results:
Statistically significant increase in WBC count in the HMG group from the start of stimulation to the midluteal phase. No statistically significant increase in the recFSH group, but only a trend towards higher values was observed.
Conclusion:
The development of a leukocytosis in controlled ovarian stimulation does not depend on the protocol used. Urinary gonadotrophins seem to have a greater potential to increase WBC count compared to recombinant gonadotrophins.